Sector
PharmaceuticalsOpen
₹1,056Prev. Close
₹1,060.2Turnover(Lac.)
₹920.28Day's High
₹1,067.4Day's Low
₹1,026.252 Week's High
₹1,36052 Week's Low
₹598Book Value
₹89.71Face Value
₹1Mkt Cap (₹ Cr.)
27,006.8P/E
95.88EPS
11.05Divi. Yield
025 Apr 2025
12:00 AM
Board Meeting
Agenda : Audited Result
29 Oct 2024
12:00 AM
EGM
12 Jul 2024
12:00 AM
BookCloser
13 Jul 2024
12:00 AM
AGM
Announcement Date: 13 Jul, 2024
Revenue from operations of the company stood at ₹307.2 crore, with a Year-on-Year (YoY) growth of 39.8% quarter over Q3 FY24 as compared to ₹219.8 crore
Suven is now a prominent player in the ADC outsourcing market, estimated to be worth $2.7 billion (approx. ₹22,815 Crore).
Here are some of the stocks that may see significant price movement today: Adani Enterprises, Siemens, Aurobindo Pharma, etc.
Here are some of the stocks that may see significant price movement today: HCL Technologies, Lupin, Piramal Pharma, etc.
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 25.46 | 25.46 | 25.46 | 25.46 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 2,030.44 | 1,723.92 | 1,495.24 | 1,039.73 |
Net Worth | 2,055.9 | 1,749.38 | 1,520.7 | 1,065.19 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2019 |
|---|---|---|---|---|
Revenue | 1,320.22 | 1,009.71 | 833.78 | 0 |
yoy growth (%) | 30.75 | 21.09 | 0 | |
Raw materials | -399.1 | -301.94 | -229.18 | 0 |
As % of sales | 30.23 | 29.9 | 27.48 | 0 |
Employee costs | -100.48 | -76.23 | -73.72 | 0 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2019 |
|---|---|---|---|---|
Profit before tax | 722.44 | 413.97 | 357.59 | -0.02 |
Depreciation | -39.09 | -31.63 | -23.86 | 0 |
Tax paid | -164.34 | -105.33 | -87.51 | 0 |
Working capital | 215.89 | 16.14 | -52.93 | |
Other operating items |
No Record Found
| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|---|
Gross Sales | 1,051.35 | 1,340.33 | 1,320.22 | 1,009.72 | 833.79 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 1,051.35 | 1,340.33 | 1,320.22 | 1,009.72 | 833.79 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 61.91 | 46.36 | 133.49 | 67.97 | 66.33 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,767.2 | 134.52 | 4,23,770.54 | 1,181.05 | 0.76 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,960.5 | 76.3 | 1,58,175.47 | 594 | 0.5 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,486.8 | 25.8 | 1,20,075.94 | 1,438.15 | 0.87 | 4,134.87 | 360.72 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,185.8 | 59.05 | 1,07,722.35 | 485 | 0.88 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,439.5 | 51.93 | 1,00,425.74 | 416.38 | 0 | 2,396.57 | 334.17 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Non Executive Director
Shweta Jalan
Independent Director
U B Pravin Rao
Managing Director
Venkatanaga Kali Vara Prasad Raju Vetukuri
Non Executive Director
Pankaj Patwari
Independent Director
Matangi Gowrishankar
Independent Director
Vinod Rao
Independent Director
K G Ananthakrishnan
Executive Chairman & Director
VIVEK SHARMA
Company Sec. & Compli. Officer
Kundan Kumar Jha
Additional Director
Jaishankar Krishnan
Additional Director
Vinod Padikkal
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Suven Pharmaceuticals Ltd
Summary
Suven Pharmaceuticals Limited (SPL) is an integrated Contract Development and Manufacturing Operations (CDMO) company that serves leading global life science and fine chemical majors. The Companys comprehensive services encompass- Custom Synthesis, Process R&D,Scale-Up, and Contract Manufacturing of intermediates, APIs, and formulations. Suven Pharmaceuticals Limited was incorporated on 6 November, 2018 and is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies. The Company has established core competencies in cyanation and heterocyclic chemistry, covering pyrimidines, quinolones, thiazoles, and imidazoles.The Company is a CDMO that supports global life sciences industry and fine chemical majors in their NCE development endeavors. Its services include custom synthesis, process R&D, scale-up and contract manufacturing of intermediates, APIs and formulations. Suven Pharma Inc., a Delaware Company, is a WOS (wholly owned subsidiary) of SPL, is a SPV (Special Purpose Vehicle) created on 9th March 2019, for undertaking various business opportunities in Pharma Industry.During the year 2019-20, Suven Life Sciences Ltd. (SLSL) has transferred the CRAMS Business Undertaking Division to the Company through the Scheme of Arrangement (Deme
Read More
What is the Suven Pharmaceuticals Ltd share price today?
The Suven Pharmaceuticals Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹1060.9 today.
What is the Market Cap of Suven Pharmaceuticals Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Suven Pharmaceuticals Ltd is ₹27006.80 Cr. as of 09 May ‘25
What is the PE and PB ratio of Suven Pharmaceuticals Ltd?
The PE and PB ratios of Suven Pharmaceuticals Ltd is 95.88 and 12.23 as of 09 May ‘25
What is the 52 Week High and Low of Suven Pharmaceuticals Ltd?
The 52-week high/low is the highest and lowest price at which a Suven Pharmaceuticals Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Suven Pharmaceuticals Ltd is ₹598 and ₹1360 as of 09 May ‘25
What is the CAGR of Suven Pharmaceuticals Ltd?
Suven Pharmaceuticals Ltd's CAGR for 5 Years at 49.11%, 3 Years at 23.25%, 1 Year at 60.37%, 6 Month at -17.67%, 3 Month at -5.08% and 1 Month at -1.99%.
What is the shareholding pattern of Suven Pharmaceuticals Ltd?
The shareholding pattern of Suven Pharmaceuticals Ltd is as follows:
Promoters - 50.10 %
Institutions - 27.67 %
Public - 22.23 %
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
